A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
Xia G, Chen W, Zhang J, Shao J, Zhang Y, Huang W, Zhang L, Qi W, Sun X, Li B, Xiang Z, Ma C, Xu J, Deng H, Li Y, Li P, Miao H, Han J, Liu Y, Shen J, Yu Y.
Xia G, et al.
J Med Chem. 2014 Dec 11;57(23):9889-900. doi: 10.1021/jm5014659. Epub 2014 Dec 1.
J Med Chem. 2014.
PMID: 25409491